Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Chondroitin sulfate/hyaluronic acid/carboxymethylcellulose macroporous cryogels for controlled delivery of TGF-β1 and IGF-1 to induce chondrogenic differentiation of adipose-derived stem cells in cartilage tissue enginee

Chen CH., Chang CJ., Kuo CY., Luo GJ., Dash BS., Govindaraju DT.

Animal Study on Cartilage Damage, published in Int J Biol Macromol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Biol Macromol (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
40449777
DOI
10.1016/j.ijbiomac.2025.144756
Citations
3

Abstract (original English)

To repair articular cartilage defects using adipose-derived stem cells (ASCs), we aim to fabricate macroporous cryogel scaffolds from chondroitin sulfate (CS) and hyaluronic acid (HA), two of the most abundant glycosaminoglycans in cartilage extracellular matrix. Carboxymethylcellulose was blended with HA and CS and crosslinked with 1,4-butanediol diglycidyl ether to prepare a supramacroporous chondroitin sulfate/hyaluronic acid/carboxymethylcellulose (CHC) cryogel. The cryogel is biodegradable and has unique mechanical properties for use as a scaffold for cartilage tissue engineering. The transforming growth factor-β1 (TGF-β1) and insulin-like growth factor-1 (IGF-1) were bound to CS for prolonged presentation of these growth factors in the scaffolds, with controlled release extended to >21 days. The TGF-β1 and IGF-1 can act in combination to regulate chondrogenic differentiation of seeded ASCs. The CHC/TGF-β1/IGF-1 cryogel scaffold promotes the chondrogenesis over CHC/TGF-β1 from cell morphology, matrix and type II collagen production. From qRT-PCR analysis, it also upregulated the gene expression of SRY-box transcription factor 9 (SOX9), type II collagen (COL2A1), aggrecan (ACAN), and proteoglycan 4 (PRG4) while downregulated the gene expression of type X collagen (COL10A1) After in vitro culture ASCs in CHC/TGF-β1/IGF-1 cryogel for 14 days, the cell/scaffold constructs were

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Tissue EngineeringHyaluronic AcidTransforming Growth Factor beta1ChondrogenesisInsulin-Like Growth Factor ICell DifferentiationCryogelsChondroitin SulfatesStem CellsAdipose Tissue

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research